http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2505270-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_42e94091a4fc81b8d0237117707cc7ee |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-437 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-541 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D513-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-14 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-437 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2010-09-02^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2014-10-09^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_18cc5c4f94be81d9bca01386b2d18286 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_06b6e46abae9ba1c66cd67eadac50e92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0d8dbbc6f30a9bc5839b9ce24f5f6d63 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2077678546890b9e3f15ff994bf58dff http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6454601b14b2f27306b1badf6a88a12c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7f2f08ffc6f3bbe111aac760ca2190d9 |
| publicationDate | 2014-10-09^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2505270-T3 |
| titleOfInvention | JAK2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer |
| abstract | A compound of the formula or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein X is C1-4 alkyl; Y is C1-4 alkyl; R is any of which is optionally condensed with a 5 or 6 membered carbocycle or heterocycle, said heterocycle having a heteroatom selected from NR3 or S, said condensed carbocycle or heterocycle optionally substituted with 0-3 R1, R1 is H, halo , CN, C1-6 alkyl substituted with 0-3 Rc, CF3, CONRaRa, NRaRa, COORb, SO2-C1-4 alkyl, C (O) Rd, cycloalkyl substituted with 0-3 Re, furanyl, tetrahydropyranyl or pyridinyl; R2 is H, C1-6 alkyl substituted with 0-3 Rc, C (O) O-C1-4 alkyl, SO2-C1-4 alkyl, cycloalkyl substituted with 0-3 Re, tetrahydropyranyl or R2 is absent; R3 is H, C (O) O-C1-4alkyl, or R3 is absent; Ra is H, C1-6 alkyl substituted with 0-3 Re, C3-6 cycloalkyl substituted with 0-3 Re, tetrahydropyranyl or dioxotetrahydrothiophenyl; Rb is H or C1-6 alkyl; Rc is H, halo, CN, OH, O-C1-4 alkyl, O-C1-4 alkyl-O-C1-4 alkyl, NH2, N (C1-4 alkyl) 2, C (O) N (C1 alkyl -4) 2, SO2-C1-4 alkyl, or morpholinyl or piperazinyl any of which is optionally substituted with 0-1 C1-4 alkyl; Rd is C1-6 alkyl or azeridinyl, azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, dioxidothiomorpholinyl or tetrahydropyranyl, any of which is substituted with 0-2 Re; and Re is H, halo, CN, C1-4 alkyl, OH, O-C1-4 alkyl, SO2-C1-4 alkyl, NHC (O) -C1-4 alkyl, morpholinyl, OC (O) -C1 alkyl 4, C (O) N (C1-4 alkyl) 2 or O-C1-4 alkyl-O-C1-4 alkyl. |
| priorityDate | 2009-09-03^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Showing number of triples: 1 to 835 of 835.